Hikma Demonstrates Support for US Pharmacists and Patient Safety
November 30 2018 - 4:36PM
Business Wire
Activities at upcoming ASHP conference include sponsorship of
important symposium advancing patient safety practices
Hikma Pharmaceuticals USA Inc., a wholly owned subsidiary of
Hikma Pharmaceuticals PLC (“Hikma”) (LSE:HIK) (NASDAQ Dubai:HIK)
(OTC:HKMPY), the multinational generic pharmaceutical company, will
demonstrate its commitment to serving the needs of US pharmacists
and to patient safety at the upcoming American Society of
Health-System Pharmacists’ (ASHP) Midyear Clinical Meeting and
Exhibition on December 2-6, 2018 in Anaheim, CA.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20181130005558/en/
“Hikma is committed to providing high-quality, affordable
medicines that help ASHP’s 45,000 members, who include pharmacists
and pharmacy technicians, in their work to improve medication use
and enhance patient safety,” said Daniel Motto, Executive Vice
President of Hikma’s US Injectables Division.
This year, Hikma will be exhibiting at Booth #567. Hikma will
also be sponsoring the Institute for Safe Medication Practices
(ISMP) symposium “Hidden Perioperative Medication Safety Risks: A
Time for Pharmacy Involvement,” featuring renowned medication
safety expert and ISMP Founder and President Michael R. Cohen. The
symposium is scheduled to take place on Monday, December 3rd, 2018
from 11:30am-1:00pm at the Anaheim Convention Center (ACC North)
Room 261, 200 Level. Copies of the presentation will be available
in the Hikma booth.
Motto continued, “We fully support The Institute for Safe
Medication Practices (ISMP’s) mission to advance patient safety by
empowering the healthcare community and consumers to prevent
medication errors. At Hikma, we are committed to helping put better
health within reach, every day. That means focusing on providing a
broad and deep portfolio of quality medicines that are available to
doctors, pharmacists and hospitals when and where they are
needed.”
Hikma has also demonstrated its support for US hospital
pharmacists through its efforts to help address a variety of US
drug shortages. During the last three years, Hikma has made
investments, hired staff and increased manufacturing capacity in
order to launch close to 20 medicines into shortage situations. In
2016 the FDA recognized Hikma with its Drug Shortage Assistance
Award for the company’s role in alleviating drug shortages.
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we’ve been creating high-quality medicines and making
them accessible to the people who need them. We're a global company
with a local presence across the United States (US), the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in
the MENA region, and through our venture capital arm, are helping
bring innovative health technologies to people around the world.
For more information, please visit www.hikma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181130005558/en/
Hikma Pharmaceuticals PLCSteven WeissSenior Director,
Communications and Public Affairs+1 732 720 2830/ +1 732 788
8279sweiss@hikma.com
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024